Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B
NCT00364182
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Adult Trials: 18+ Years
- Documented history of moderately severe or severe hemophilia B (FIX:C less than or equal to 2%)
- Male subjects, aged 6 years to 65 years.
- Subjects with a minimum of 12 bleeding episodes, 6 of which must be joint bleeds, in the 12 months before screening.
- Subjects currently utilizing FIX primary prophylaxis.
- Subjects with HIV+ who have a CD4 count less than 200
- Subjects with hepatic or renal impairment.
- Prothrombin time or International Normalized Ration more than 1.5 times the upper
limit of normal.
- Major surgery or an orthopedic surgical procedure within the past 3 months or is
planned within the duration of participation in this study.
- Past history of, or current FIX inhibitor.
- Hypersensitivity to any FIX product or hamster protein.
- Exposure to any investigational drug, except for rFIX-R, or device within 30 days of
providing consent/assent (as appropriate) for this study.
- Bleeding disorders other than hemophilia B.
- Concurrent inflammatory disease that in the investigator's judgment could confound the
study results.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Chamberry, Cedex
- Le Chesnay, Cedex
- Caen Cedex 9,
- Clermont Ferrand,
- Dijon Cedex,
- leKremlin-Bicetre,
- Lyon,
- Marseille Cedex 05,
- Montmorency,
- Montpellier Cedex 5,
- Nantes cedex 1,
- Paris,
- Paris,
- Rouen,
- Saint Priest en Jarez,
- Tours,
- Vandoeuvre Les Nancy Cedex,
- Phoenix, Arizona
- Chicago, Illinois
- Chicago, Illinois
- New Brunswick, New Jersey
- Houston, Texas
- Edmonton, Alberta
- Edmonton, Alberta
- Ottawa, Ontario
- Zagreb,
- Budapest,
- Castelfranco Veneto (TV),
- Coppito (AQ),
- Bucuresti,
- Moscow,
- Saint Petersburg,
- Belgrade,
- Nis,
- Madrid,
- Sevilla,
- Los Angeles, California
- Aurora, Colorado
- Detroit, Michigan
- New Brunswick, New Jersey
- Chapel Hill, North Carolina
- Dayton, Ohio
- Houston, Texas
- Shinjuku-ku, Tokyo
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B | |||
| Official Title ICMJE | A Multicenter, Open-Label Study To Compare On-Demand Treatment With 2 Prophylaxis Regimens of Recombinant Coagulation Factor IX (BeneFIX) Reformulated Drug Product (rFIX-R) In Subjects With Severe Hemophilia B | |||
| Brief Summary | This study is designed to evaluate BeneFIX infused as prophylaxis regimens, compared with BeneFIX administered as an on-demand regimen only. In the trial, subjects will participate in 4 study periods. The first period is a 16-week on-demand treatment, during which subjects will utilize BeneFIX to treat bleeding events episodically only as they occur (i.e., on-demand treatment). At the end of this period, subjects will be randomly assigned to 1 of 2 BeneFIX prophylaxis regimens: either 100 IU/kg once weekly or 50 IU/kg twice weekly, and followed for 16 weeks. At the end of this period, subjects will use on-demand treatment for 8 weeks. The purpose of this 8-week period is to mitigate the potential carry-over effect of the prior prophylaxis regimen on bleeding frequency. Following this 8-week on-demand treatment, subjects will cross-over and receive the alternate study prophylactic regimen for 16 weeks. The primary endpoint is annualized number of bleeding episodes, compared between the first on-demand period and each of the prophylaxis regimens. A comparison of annualized bleeding episodes between the two prophylaxis regimens will also be performed. Subject-reported outcomes will also be collected using a patient diary. At 24 and 48 hours following the onset of each joint bleeding episode, information on pain, sleep, and work will be collected. Additional data on physical functioning will be recorded on the diary at the end of the 16-week on-demand period, and at the end of each prophylaxis period. Information on safety will also be collected. Each subject will participate in this study for approximately 59 weeks (15 months), including a screening period of up to 3 weeks, an initial 16-week on-demand period, two prophylaxis treatment periods of 16 weeks each, separated by an 8-week on-demand treatment period. A modified FIX recovery study will be performed once during each prophylaxis period. The study diary will also be used by subjects to collect secondary endpoints. These endpoints, which are subject-reported outcomes, will be recorded in the diary at 24 and 48 hours following the onset of each joint bleeding episode. Additional data on physical functioning will be recorded on the diary at the end of the 16-week on-demand period, and at the end of each prophylaxis period. Patients will be recruited in the United States, Canada, Europe and Russia. | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 3 | |||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Crossover Assignment Masking: None (Open Label) Primary Purpose: Prevention | |||
| Condition ICMJE | Hemophilia B | |||
| Intervention ICMJE |
| |||
| Study Arms ICMJE |
| |||
| Publications * |
| |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Actual Enrollment ICMJE | 50 | |||
| Original Enrollment ICMJE | 40 | |||
| Actual Study Completion Date ICMJE | October 2010 | |||
| Actual Primary Completion Date | October 2010 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 6 Years to 65 Years (Child, Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | Canada, Croatia, Hungary, Italy, Romania, Russian Federation, Serbia, Spain, United States | |||
| Removed Location Countries | Belgium, Germany | |||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00364182 | |||
| Other Study ID Numbers ICMJE | 3090A1-400 B1821002 ( Other Identifier: Pfizer ) | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Pfizer | |||
| Study Sponsor ICMJE | Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Pfizer | |||
| Verification Date | August 2011 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||